TCL1A Antilichaam - N-terminalgebied: FITC (ARP58808 P050-FITC)

T-cell leukemia/lymphoma 1A

TCL1

8115

P56279

NP_068801

Human

The immunogen is a synthetic peptide directed towards the N terminal region of human TCL1A

TCL1A can enhance the phosphorylation and activation of AKT1, AKT2 and AKT3; promote nuclear translocation of AKT1; enhance cell proliferation, stabilize mitochondrial membrane potential and promote cell survival.

TXLNA; TXLNB; ALS2CR12; CARD9; PRTFDC1; CEP55; LSM3; TTC33; WDR47; CALCOCO2; CADPS; TCL1A; TRAF1; TP53BP2; TCF4; GOLGA2; DNMT3A; AKT1; JUNB; JUN; FOS; EP300; ATM; HIST3H2A; AKT3; AKT2

FITC: Fluorescein Isothiocyanate

Polyclonal Antibody

WB

Affinity Purified

0.5 mg/ml

Human: 100%

Liquid. Purified antibody supplied in 1x PBS buffer.

All conjugated antibodies should be stored in light-protected vials or covered with a light protecting material (i.e. aluminum foil) . Conjugated antibodies are stable for at least 12 months at 4C. If longer storage is desired (24 months), conjugates may be diluted with up to 50% glycerol and stored at -20C to -80C. Freezing and thawing conjugated antibodies will compromise enzyme activity as well as antibody binding.

13kDa

Herling, M., (2008) Blood 111 (1), 328-337

Wet Ice

114

TCL1A

TCL1A

Rabbit

T-cell leukemia/lymphoma protein 1A

NM_021966

MAECPTLGEAVTDHPDRLWAWEKFVYLDEKQHAWLPLTIEIKDRLQLRVL